Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome

Sponsor
Pfizer (Industry)
Overall Status
Completed
CT.gov ID
NCT00002074
Collaborator
(none)
39

Study Details

Study Description

Brief Summary

To compare the safety and effectiveness of fluconazole and amphotericin B as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Concurrent Medication:
    Allowed:
    • Antivirals such as zidovudine.

    • Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia (PCP).

    • Pfizer must be notified if the patient is receiving ganciclovir (DHPG) at entry.

    Concurrent Treatment:
    Allowed:
    • Radiation therapy for mucocutaneous Kaposi's sarcoma.

    Patients must be oriented to person, place, and time, and able to give written informed consent.

    • Patients must have had an acute episode of cryptococcal meningitis that was documented by recovery and identification of Cryptococcus neoformans from lumbar cerebrospinal fluid (CSF) culture within 6 months prior to entry.

    • Minimum total dose of 15 mg/kg of amphotericin B must have been given (either alone or in combination with flucytosine) during primary therapy.

    • Patients need not be receiving amphotericin B at the time of randomization but must begin study maintenance therapy within 6 weeks of completion of primary amphotericin B therapy. Patients may receive maintenance amphotericin B during the period between completion of primary therapy and study entry.

    Prior Medication:
    Allowed:
    • Antivirals such as zidovudine (AZT).

    • Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia (PCP).

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following are excluded:
    • Clinical evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.

    • History of allergy or intolerance of imidazoles, azoles, or amphotericin B.

    • Moderate or severe liver disease.

    Concurrent Medication:
    Excluded:
    • Ketoconazole.

    • Fluconazole.

    • Itraconazole.

    • Miconazole.

    • Any systemic imidazole or azole for more than 7 days after initiation of primary therapy for cryptococcosis.

    • Intrathecal amphotericin B.

    • Coumarin-type anticoagulants.

    • Oral hypoglycemics.

    • Barbiturates.

    • Phenytoin.

    • Immunostimulants.

    • Investigational drugs or approved (licensed) drugs for investigational indications.

    Concurrent Treatment:
    Excluded:
    • Lymphocyte replacement.
    Patients with the following are excluded:
    • Clinical evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.

    • History of allergy or intolerance of imidazoles, azoles, or amphotericin B.

    • Moderate or severe liver disease.

    • Inability to take oral medications reliably.

    Prior Medication:
    Excluded:
    • Ketoconazole.

    • Fluconazole.

    • Itraconazole.

    • Miconazole.

    • Any systemic imidazole or azole for more than 7 days after initiation of primary therapy for cryptococcosis.

    • Intrathecal amphotericin B.

    • Coumarin-type anticoagulants.

    • Oral hypoglycemics.

    • Barbiturates.

    • Phenytoin.

    • Immunostimulants.

    • Investigational drugs or approved (licensed) drugs for investigational indications.

    • Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research.

    Prior Treatment:
    Excluded:
    • Lymphocyte replacement.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Univ of Alabama at Birmingham Birmingham Alabama United States 35294
    2 Tucson Veterans Administration Med Ctr Tucson Arizona United States 85724
    3 Dr Richard Meyer Los Angeles California United States 90048
    4 Davies Med Ctr San Francisco California United States 94114
    5 Dr Paul Rothman Sherman Oaks California United States 91403
    6 Wilmington Hosp / Med Ctr of Delaware Wilmington Delaware United States 19899
    7 George Washington Univ Med Ctr Washington District of Columbia United States 20037
    8 Univ of Florida College of Medicine Gainesville Florida United States 32610
    9 Univ of South Florida Tampa Florida United States 33612
    10 Emory Univ School of Medicine Atlanta Georgia United States 30303
    11 Med College of Georgia Augusta Georgia United States 30912
    12 DeKalb Gen Hosp Decatur Georgia United States 30033
    13 Shallowford Hosp Decatur Georgia United States 30033
    14 Northwestern Univ Med School Chicago Illinois United States 60611
    15 Dr Michael Bach Portland Maine United States 04102
    16 Univ of Maryland / Inst of Human Virology Baltimore Maryland United States 212011192
    17 New England Med Ctr Boston Massachusetts United States 02111
    18 Univ Hosp Boston Massachusetts United States 02118
    19 Ann Arbor Veterans Administration Med Ctr Ann Arbor Michigan United States 48105
    20 Harper Hosp Detroit Michigan United States 48201
    21 Henry Ford Hosp Detroit Michigan United States 48202
    22 Saint Michael's Med Ctr Newark New Jersey United States 07102
    23 Albany Med College / AIDS Treatment Ctr Albany New York United States 12203
    24 Jewish Hosp Ctr Affiliation Jamaica New York United States 11432
    25 Cabrini Med Ctr New York New York United States 10003
    26 Chelsea Village Med Ctr New York New York United States 10014
    27 Columbia Univ New York New York United States 10032
    28 Harlem AIDS Treatment Group / Harlem Hosp Ctr New York New York United States 10037
    29 Bowman Gray School of Medicine / North Carolina Baptist Hosp Winston-Salem North Carolina United States 27103
    30 Cincinnati Veterans Adm Med Ctr / Univ Hosp Cincinnati Ohio United States 452670405
    31 Buckley Braffman Stern Med Associates Philadelphia Pennsylvania United States 19107
    32 Univ TX Galveston Med Branch Galveston Texas United States 77550
    33 United States Air Force Med Ctr Lackland Air Force Base Texas United States 782365300
    34 Southwest Texas Methodist Hosp San Antonio Texas United States 78229
    35 Univ TX San Antonio Health Science Ctr San Antonio Texas United States 78284
    36 Richmond AIDS Consortium Richmond Virginia United States 23219
    37 CHG-118 Group Health / Cooperative of Puget Sound Seattle Washington United States 98112
    38 Dr Philip C Craven Tacoma Washington United States 98405
    39 Saint Michael's Hosp Toronto Ontario Canada

    Sponsors and Collaborators

    • Pfizer

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002074
    Other Study ID Numbers:
    • 012D
    • 056-157
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    May 1, 1990

    Study Results

    No Results Posted as of Jun 24, 2005